| Toxicology |
1 |
1 |
| Skin Cancer |
0 |
0.98 |
| Cancer |
0 |
0.81 |
| Squamous Cell Carcinoma |
0 |
0.62 |
| Biologic Therapy |
0 |
0.53 |
| Clinical Research |
0 |
0.51 |
| Lung Cancer |
0 |
0.81 |
| Nonmelanoma Skin Cancer |
0 |
0.47 |
| Genomic Medicine |
0 |
0.35 |
| Dermatoses |
0 |
0.6 |
| Immunocompromise |
0 |
0.29 |
| Melanoma |
0 |
0.7 |
| Dermatitis |
0 |
0.25 |
| Patient Safety |
0 |
0.23 |
| Adverse Effects |
0 |
0.22 |
| Id Reaction |
0 |
0.15 |
| EGFR Inhibitor |
0 |
0.13 |
| Revenue and Practice Management |
0 |
0.13 |
| Epidermal Growth Factor Receptor |
0 |
0.1 |
| Actinic Keratosis |
0 |
0.07 |
| Bullous Pemphigoid |
0 |
0.07 |
| Drug Eruption |
0 |
0.07 |
| Erythroderma |
0 |
0.07 |
| Florida |
0 |
0.07 |
| Glucocorticoid |
0 |
0.07 |
| Health Care Quality, Access, and Evaluation |
0 |
0.07 |
| Hospital |
0 |
0.07 |
| Immunosuppressive Therapy |
0 |
0.07 |
| Immunotherapy |
0 |
0.07 |
| Insurance |
0 |
0.07 |
| Lichen Planus |
0 |
0.07 |
| Lung |
0 |
0.07 |
| Massachusetts |
0 |
0.07 |
| Match |
0 |
0.07 |
| Mucositis |
0 |
0.07 |
| Pruritus |
0 |
0.07 |
| Quality of Life |
0 |
0.07 |
| Receptors |
0 |
0.07 |
| Stevens-Johnson Syndrome |
0 |
0.07 |
| Vitiligo |
0 |
0.07 |
| Social Determinants of Health |
0 |
0.06 |